{"id":53230,"date":"2023-09-20T09:44:00","date_gmt":"2023-09-20T09:44:00","guid":{"rendered":"https:\/\/medsname.com\/chemlet\/"},"modified":"2026-04-30T16:30:24","modified_gmt":"2026-04-30T16:30:24","slug":"chemlet","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/chemlet\/","title":{"rendered":"Chemlet"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Chemlet<\/strong> \u2014 Letrozole 2.5 mg (WHO-GMP certified manufacturer). Aromatase inhibitor for hormone-receptor-positive (HR+) breast cancer in post-menopausal women \u2014 adjuvant, extended adjuvant, and metastatic settings. Once-daily oral.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/li>\n<li>\u03a3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03cc \u03c6\u03ac\u03ba\u03b5\u03bb\u03bf \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/li>\n<li>\u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/li>\n<li>\u0391\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 (<a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03b4\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>\u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2:<\/strong> \u03b1\u03bd \u03b7 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03bc\u03ad\u03c3\u03b1 \u03c3\u03b5 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c4\u03b7\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c0\u03c1\u03cc\u03c3\u03b8\u03b5\u03c4\u03bf \u03ba\u03cc\u03c3\u03c4\u03bf\u03c2. <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\">\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae<\/a>.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Chemlet ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor \u2014 never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specialist-supervised cancer therapy<\/strong> \u2014 this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Post-menopausal only<\/strong><br \/>AIs are NOT effective in pre-menopausal women \u2014 without ovarian suppression, ovaries override AI inhibition. Pre-menopausal HR+ breast cancer requires tamoxifen \u00b1 ovarian suppression (LHRH agonist) or AI WITH ovarian suppression as a specialist-supervised regimen.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Bone density loss + cardiovascular risk<\/strong><br \/>AIs accelerate bone density loss and fracture risk. Baseline DEXA is recommended; consider bisphosphonate (zoledronic acid, ibandronate) or denosumab in osteopenia\/osteoporosis. AIs may modestly raise lipid levels and cardiovascular events vs tamoxifen. Monitor lipids and cardiovascular risk factors annually.<\/div>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>AI vs tamoxifen \u2014 which is better?<\/h3>\n<p>In post-menopausal HR+ breast cancer, AIs (anastrozole, letrozole, exemestane) give modestly higher disease-free survival than tamoxifen (ATAC, BIG 1-98, MA.17). AIs are preferred adjuvant in most post-menopausal women; tamoxifen remains preferred in pre-menopausal disease and in patients with severe AI side effects.<\/p>\n<h3>How long is treatment?<\/h3>\n<p>Adjuvant therapy is typically 5 years; some women benefit from extended adjuvant (5-10 years total) based on ATLAS\/MA.17 data. Specialist decides extended therapy based on recurrence risk.<\/p>\n<h3>Common side effects?<\/h3>\n<p>Hot flushes, joint and muscle pain (arthralgia\/myalgia \u2014 affects 30-50%, often improves with continued therapy), fatigue, vaginal dryness, mood changes, accelerated bone loss.<\/p>\n<h3>Joint pain \u2014 is it serious?<\/h3>\n<p>AI-related arthralgia is the most common reason for non-adherence. Often improves over 3-6 months; symptomatic relief with NSAIDs, exercise, occasionally switching between AIs (anastrozole \u2194 letrozole \u2194 exemestane). Vitamin D + calcium adequacy helps.<\/p>\n<h3>What if I&#8217;m pre-menopausal?<\/h3>\n<p>AIs alone do not work \u2014 ovaries override. Discuss tamoxifen, or AI + ovarian suppression, with your specialist.<\/p>\n<h3>\u03a0\u03c5\u03ba\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 \u03bf\u03c3\u03c4\u03ce\u03bd;<\/h3>\n<p>Mandatory baseline DEXA. Repeat every 1-2 years. Add a bisphosphonate or denosumab if osteopenia or osteoporosis develops, or in high baseline-risk patients prophylactically.<\/p>\n<h3>Side effects vs exemestane?<\/h3>\n<p>Anastrozole and letrozole are non-steroidal AIs (reversible). Exemestane is a steroidal AI (irreversible inactivator). Side-effect profiles broadly similar; some women prefer one over another. Switching is reasonable for tolerability.<\/p>\n<h3>Vaginal dryness?<\/h3>\n<p>Common. Topical vaginal moisturisers and water-based lubricants help. Topical oestrogen (very low dose, vaginal) is generally avoided in HR+ breast cancer; if symptoms severe, discuss with oncologist \u2014 vaginal DHEA, ospemifene, or specialist menopause review may be options.<\/p>\n<h3>\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd;<\/h3>\n<p>Few major. CYP-modulators have minimal effect on AIs. Tamoxifen and AIs should NOT be combined (no benefit). Always disclose all medications.<\/p>\n<h3>\u03a4\u03b9 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03b1\u03bd \u03c7\u03ac\u03c3\u03c9 \u03bc\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7;<\/h3>\n<p>Take when you remember if same day; otherwise skip. Do not double up. Consistent daily dosing maximises effect.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Cancer &#038; Hormonal Therapy Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/xeloda\/\">Xeloda<\/a> \u2014 capecitabine 500 mg \u2014 oral 5-FU prodrug for breast\/colorectal\/gastric cancers<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/altraz\/\">Altraz<\/a> \u2014 anastrozole 1 mg \u2014 aromatase inhibitor for post-menopausal breast cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/xbira\/\">Xbira<\/a> \u2014 abiraterone 250 mg \u2014 CYP17 inhibitor for metastatic prostate cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zoldria\/\">Zoldria<\/a> \u2014 zoledronic acid IV \u2014 for bone metastases and hypercalcaemia<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 for chemotherapy-induced anaemia<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>\u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd:<\/strong> Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.<\/div>","protected":false},"excerpt":{"rendered":"<p>Chemlet (Letrozole 2.5 mg) \u2014 non-steroidal aromatase inhibitor for HR+ breast cancer in post-menopausal women. Slightly different toxicity profile to anastrozole; switching may help arthralgia.<\/p>","protected":false},"featured_media":53231,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53230","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/53230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=53230"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/53231"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=53230"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=53230"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=53230"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=53230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}